PARP Inhibitor Combination Approaches in Prostate Cancer: Interpretation of Clinical Findings and Regulatory Approvals

Expert insight on integrating PARP inhibitor combination therapy into clinical practice for patients with prostate cancer including a downloadable slideset, interactive webcast, and expert commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA